{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:59:50Z","timestamp":1771210790022,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMS1915829"],"award-info":[{"award-number":["DMS1915829"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.08.055","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T05:23:11Z","timestamp":1662355391000},"page":"5912-5923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0347","authenticated-orcid":false,"given":"Li","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-4572","authenticated-orcid":false,"given":"Yanqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-2915","authenticated-orcid":false,"given":"Michal","family":"Juraska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-2664","authenticated-orcid":false,"given":"Craig A.","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-7873","authenticated-orcid":false,"given":"Fei","family":"Heng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2022.08.055_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/srep36339","article-title":"Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans","volume":"6","author":"Fleith","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.055_b0010","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tim.2013.12.011","article-title":"Global spread of dengue virus types: mapping the 70 year history","volume":"22","author":"Messina","year":"2014","journal-title":"Trends Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.055_b0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CMR.00035-09","article-title":"Dengue virus pathogenesis: an integrated view","volume":"22","author":"Martina","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.055_b0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.055_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni.3081","article-title":"Broad and strong: the ultimate antibody to dengue virus","volume":"16","author":"Coloma","year":"2015","journal-title":"Nat Immunol"},{"issue":"120","key":"10.1016\/j.vaccine.2022.08.055_b0030","first-page":"653","article-title":"outbreak","volume":"1984","author":"Sangkawibha","year":"1980","journal-title":"Am J Epidemiol"},{"issue":"9966","key":"10.1016\/j.vaccine.2022.08.055_b0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"issue":"9951","key":"10.1016\/j.vaccine.2022.08.055_b0040","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.055_b0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.055_b0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.055_b0055","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.08.055_b0060","doi-asserted-by":"crossref","unstructured":"Plotkin SA, Gilbert PB. Correlates of protection. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's vaccines. 7th Ed. Elsevier; 2018 [chap. 3].","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.055_b0065","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.055_b0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.055_b0075","doi-asserted-by":"crossref","first-page":"e0234236","DOI":"10.1371\/journal.pone.0234236","article-title":"Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America","volume":"15","author":"Carpp","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.08.055_b0080","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/v3091562","article-title":"Dengue\u2013quo tu et quo vadis?","volume":"3","author":"Chen","year":"2011","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.055_b0085","doi-asserted-by":"crossref","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","article-title":"Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization","volume":"6","author":"Messer","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2022.08.055_b0090","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1128\/JVI.01190-10","article-title":"Genotype-specific neutralization and protection by antibodies against dengue virus type 3","volume":"84","author":"Brien","year":"2010","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.055_b0095","doi-asserted-by":"crossref","first-page":"e1000823","DOI":"10.1371\/journal.ppat.1000823","article-title":"The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1","volume":"6","author":"Shrestha","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2022.08.055_b0100","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24196","article-title":"Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy","volume":"6","author":"Rabaa","year":"2017","journal-title":"Elife"},{"issue":"36","key":"10.1016\/j.vaccine.2022.08.055_b0105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.055_b0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.055_b0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2022.08.055_b0120","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.055_b0125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.055_b0130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/rssc.12417","article-title":"A hybrid approach for the stratified mark-specific proportional hazards model with missing covariates and missing marks, with application to vaccine efficacy trials","volume":"69","author":"Sun","year":"2020","journal-title":"J R Stat Soc Appl Stat Ser C"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.055_b0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12561-016-9177-5","article-title":"Estimation of stratified mark-specific proportional hazards models under two-phase sampling with application to HIV vaccine efficacy trials","volume":"9","author":"Yang","year":"2017","journal-title":"Stat Biosci"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.055_b0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/bimj.201700002","article-title":"Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials","volume":"60","author":"Sun","year":"2018","journal-title":"Biom J"},{"issue":"45","key":"10.1016\/j.vaccine.2022.08.055_b0145","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.055_b0150","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4161\/hv.25562","article-title":"Persistence of Th1\/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore","volume":"9","author":"Harenberg","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.08.055_b0155","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.055_b0160","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic variation between dengue virus type 4 strains impacts human antibody binding and neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2022.08.055_b0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2020.07.006","article-title":"Mapping the diverse structural landscape of the flavivirus antibody repertoire","volume":"45","author":"Sevvana","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.08.055_b0170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52384","article-title":"Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics","volume":"8","author":"Durham","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2022.08.055_b0175","doi-asserted-by":"crossref","unstructured":"Pinheiro JR, Camilo Dos Reis E, Souza R, Rocha ALS, Suesdek L, Azevedo V, et al. Comparison of neutralizing dengue virus B cell epitopes and protective T cell epitopes with those in three main dengue virus vaccines. Front Immunol 2021;12:715136.","DOI":"10.3389\/fimmu.2021.715136"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.055_b0180","doi-asserted-by":"crossref","first-page":"e1009331","DOI":"10.1371\/journal.ppat.1009331","article-title":"Antibody affinity versus dengue morphology influences neutralization","volume":"17","author":"Fibriansah","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2022.08.055_b0185","doi-asserted-by":"crossref","unstructured":"Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, et al. Identification of dengue virus serotype 3 specific antigenic sites targeted by neutralizing human antibodies. Cell Host Microbe 2020;27:710\u201324 e7.","DOI":"10.1016\/j.chom.2020.04.007"},{"issue":"13","key":"10.1016\/j.vaccine.2022.08.055_b0190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:22Z","timestamp":1759403962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2201043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":38,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X2201043X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}